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OBJECTIVE—Metformin, an oral glucose-lowering drug, is
taken up in hepatocytes by the organic cation transporter
(OCT) 1 and in renal epithelium by OCT2. In these cells, the
multidrug and toxin extrusion (MATE) 1 protein, encoded by
the SLC47A1 gene, is responsible for the excretion of met-
formin into the bile and urine, respectively. We studied the
effect of single nucleotide polymorphisms (SNPs) in the
SLC47A1 gene on the A1C-lowering effect of metformin.
RESEARCH DESIGN AND METHODS—We identiﬁed all in-
cident metformin users in the Rotterdam Study, a population-
based cohort study. Associations between 12 tagging SNPs in the
SLC47A1 gene and change in A1C level were analyzed.
RESULTS—One hundred and sixteen incident metformin users
were included in the study sample. The rs2289669 GA SNP was
signiﬁcantly associated with metformin response. For the other
SNPs, no associations were found. For each minor A allele at
rs2289669, the A1C reduction was 0.30% (95% CI 0.51 to 0.10;
P  0.005) larger. After Bonferroni correction for multiple
testing, the P value was 0.045.
CONCLUSIONS—The rs2289669 GA SNP is associated with
a reduction in A1C level, consistent with a reduction in MATE1
transporter activity. These results suggest that the transporter
MATE1, encoded by SLC47A1, may have an important role in
the pharmacokinetics of metformin, although replication is
necessary. Diabetes 58:745–749, 2009
M
etformin is an oral glucose-lowering drug,
widely used for the treatment of type 2 dia-
betes (1). The molecular mechanism of the
glucose-lowering effect is not fully under-
stood, although it is known that inhibition of the hepatic
gluconeogenesis has an important role (2). Metformin is
mainly eliminated by tubular secretion, and hepatic me-
tabolism has a minor role.
Several drug transporters are involved in the distribu-
tion and excretion of metformin (3). The role of two
organic cation transporters (OCTs), OCT1 and OCT2, is
assumed. OCT1 and OCT2 are members of the solute
carrier (SLC) 22 family and encoded by the SLC22A1 and
SLC22A2 genes, respectively, with gene location 6q25.3.
OCT1 is expressed in the basolateral membrane of hepa-
tocytes, and the uptake of metformin in the hepatocytes by
OCT1 is an essential step for the glucose-lowering effect
(4–6). In OCT1 gene knockout mice, the metformin liver
concentrations were lower and the glucose-lowering effect
impaired (4,7). Genetic variations in the SLC22A1 gene
(R61C, G401S, M420del, and G465R) are associated with
differences in metformin plasma levels and glucose con-
centrations after an oral glucose tolerance test in healthy
volunteers (4,7). OCT2 is expressed in the basolateral
membrane of the renal epithelium, and transportation of
metformin over this membrane may be the ﬁrst step to
tubular secretion (8,9). Genetic variations in SLC22A2
(T199I, T201M, and A270S) are associated with decreased
renal excretion and increased plasma concentrations of
metformin (10,11).
Recently, a multidrug and toxin extrusion (MATE)
transporter protein family was identiﬁed, assigned as the
SLC 47 family (12,13). The SLC47A1 gene, with gene
location 17p11.2, encodes the MATE1 transporter. Met-
formin is one of the substrates of this transporter (14).
MATE1 is located in the bile canalicular membrane in the
hepatocyte and in the brush border of the renal epithelium
and is responsible for the ﬁnal step of metformin excretion
through the bile and urine (12). Another transporter in this
family is MATE2-K, encoded by SLC47A2. MATE2-K is
located in the brush border of the renal epithelium and
may also be involved in metformin excretion (14).
The colocalization of OCT1 and MATE1 in the hepato-
cyte and OCT2 and MATE1 in the renal epithelium sug-
gests that MATE1 may have an important inﬂuence on the
pharmacokinetics of metformin. The intrahepatic uptake
of metformin by OCT1 is an essential step in the glucose-
lowering effect, while the excretion out of the hepatocyte
into the bile by MATE1 probably averts this. The uptake in
the renal epithelium by OCT2 and subsequent excretion by
MATE1 are two consecutive steps in the tubular secretion
of metformin.
Little is known about the effect of genetic variation in
the SLC47A1 gene on the glucose-lowering effect of met-
formin. In this prospective, population-based cohort study,
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otide polymorphisms (SNPs) in the SLC47A1 gene and
metformin response in Caucasian incident metformin
users.
RESEARCH DESIGN AND METHODS
Data for these analyses were obtained from the Rotterdam Study, a prospec-
tive population-based cohort study of 7,983 Caucasians aged 55 years in the
suburb Ommoord in Rotterdam. Participants were invited between 1990 and
1993 and have been continuously followed since then. All participants of the
Rotterdam Study gave written informed consent. Ethical approval was ob-
tained from the medical ethical committee of the Erasmus Medical Center.
The aim of the study was to investigate determinants of chronic and disabling
cardiovascular, neurodegenerative, locomotor, endocrine, and ophthalmo-
logic diseases. The rationale, ethical approval, and design of this study have
been described before (15,16). Seven pharmacies in Ommoord dispense the
prescriptions of more than 99% of all participants. Information on all ﬁlled
prescriptions from 1 January 1991 until 1 January 2008 was available and
included the product name of the drug, the anatomical therapeutical chemical
code, the amount dispensed, the prescribed dosage regimen, and the date of
dispensing (17).
For this study, we used the A1C assessments from the Stichting Trombose-
dienst en Artsenlaboratorium Rijnmond–Medisch Diagnostisch Centrum
(STAR-MDC), which performs all outpatient laboratory assessments for
general practitioners in the Rijnmond area of Rotterdam. Hereby, we obtained
all outpatient A1C assessments from all participants between 1 April 1997, the
time at which a new computer system was introduced at STAR-MDC, and 1
January 2008. The A1C levels were measured by high-performance liquid
chromatography on a BiaRad Variant and from October 2004 onwards on a
Menarini HA8160, according to professional standards and quality. The
STAR-MDC is a CCKL-certiﬁed laboratory, and the quality is continuously
monitored by internal and external quality-assurance programs.
All participants in the Rotterdam Study, who were incident metformin
users in the period between 1 April 1997 and 1 January 2008, were included in
this analysis. Incident metformin use was deﬁned as a ﬁrst-dispensed pre-
scription for metformin in the database, which included all prescriptions from
1 January 1991 onwards. The study sample consisted of all incident metformin
users who had a measurement of A1C both in the period of 90 days before the
ﬁrst prescription of metformin and in the period between 30 and 120 days
following the ﬁrst prescription of metformin. Patients who discontinued
metformin therapy before the ﬁrst measurement after 30 days were excluded.
We also excluded patients who were coprescribed acarbose, rosiglitazone,
pioglitazone, or insulin at the time of one of the two A1C measurements
because deﬁned daily doses for these drugs are not similar and these patients
most likely differ in their severity of disease. Patients using sulfonylurea were
not excluded.
Outcomes. The aim of antihyperglycemic therapy is to reduce plasma glucose
levels. The A1C level is the percentage of hemoglobin in the blood that is
glycosylated and represents the average glucose level in the preceding period
of time. Since the A1C level is a more stable measurement of glycemic control
than plasma glucose levels, A1C levels are used more frequently for long-term
therapeutic purposes. We analyzed the association between genetic variation
in the SLC47A1 gene and difference in A1C level between the last A1C
measurement before start of metformin therapy and the ﬁrst A1C measure-
ment after 30 days of metformin therapy. The target level for diabetic patients
is an A1C level 7% (18).
Cofactors. Characteristics considered as potential determinants affecting the
change in A1C level were age, sex, the A1C level at the last measurement
before start of metformin, the daily prescribed dose of metformin at the time
of the ﬁrst measurement after start, the change in daily prescribed dose of
sulfonylurea, the time from diabetes diagnosis to start of metformin therapy,
and the estimated glomerular ﬁltration rate. To make the prescribed doses of
different sulfonylurea comparable with each other, we divided the prescribed
daily dose by the deﬁned daily dose (17). The deﬁned daily dose is a
standardized dosing measure representing the recommended daily dose for
the main indication in an adult. For the diabetes diagnosis, the World Health
Organization deﬁnition was used (19). If patients were diagnosed with
diabetes before entrance in the Rotterdam Study, the date of entrance was
used. The estimated glomerular ﬁltration rate was estimated from the serum
creatinine level at baseline with the Cockcroft-Gault formula.
Genotyping. Participants were genotyped using the Illumina 550k SNP array
according to the manufacturer’s instruction. Quality controls and results of
the genotyping were previously described (20). The tagging SNPs on the array
were selected using an algorithm with which, in a Caucasian population, 90%
of all phase I and II Hapmap SNPs are covered by at least one SNP on the array
(21–23). This coverage arises because genetic variation is transmitted in
blocks, in which haplotype alleles exist. Within these haplotypes, variant
alleles are associated with each other. This more frequent occurrence of
combinations of variant alleles than would be expected from a random
formation is called linkage disequilibrium. For this study, we selected the
tagging SNPs in the SLC47A1 gene, including the tagging SNPs within 10
kilobasepairs (kbp) of the gene that were on the array.
Statistical analysis. Deviations from Hardy-Weinberg equilibrium and dif-
ferences in genotypes between patients who continued and discontinued
metformin therapy were analyzed using 
2 tests. We used one-way ANOVA to
test for differences in average time between the last A1C measurement and
start of metformin therapy and in the average time between metformin start
and the ﬁrst A1C measurement after start. Linear regression was used to
analyze differences in A1C change between genotypes. For each polymor-
phism, we calculated the association between the number of variant alleles
and the difference in A1C change. We adjusted for multiple testing with the
Bonferroni correction, multiplying the P value by the number of independent
tests. Two or more SNPs that were in strong linkage disequilibrium (r
2  0.80)
were counted as one independent test. For the associations that were
statistically signiﬁcant after Bonferroni correction, we calculated separately
the difference between patients with one variant allele and those with the
wild-type genotype and the difference between patients with two variant
alleles and those with the wild-type genotype. The analyses were performed
with SPSS software (version 11.0.1; SPSS, Chicago, IL).
RESULTS
One hundred and eighty-one participants of the Rotterdam
Study were incident metformin users between 1 April 1997
and 1 January 2008 and had an A1C measurement both in
the period of 90 days before start and in the period
between 30 and 120 days after the start of metformin
therapy. Seven patients were excluded because they were
prescribed insulin at the time of one of the A1C measure-
ments, and six patients were excluded because they were
prescribed acarbose (n  1), rosiglitazone (n  3), or
pioglitazone (n  2). Blood samples for genotyping were
not available for 34 patients, and 18 patients discontinued
metformin therapy before the ﬁrst A1C measurement in
the period between 30 and 120 days after start. Eventually,
we included 116 incident metformin users in the analysis,
for whom the change in A1C levels was available (Table 1).
The average initial starting dose was (means  SD) 648 
310 mg metformin. At the time of the ﬁrst A1C measure-
ment after start, the participants were prescribed, on
average, 741  358 mg metformin.
The average time from the last A1C measurement before
start and start of metformin therapy was 12  16 days and
the average time from start of metformin therapy to the
ﬁrst measurement after start was 66  25 days. These
times did not differ signiﬁcantly between genotypes. The
average A1C level before start of metformin therapy was
TABLE 1
Baseline characteristics of the study population (n  116)
Sex
Male 47 (41)
Female 69 (59)
Age (years) 76.8  6.7
A1C level (%)* 8.3  1.2
BMI (kg/m
2)†‡ 28.3  3.7
Creatinine level (mol/l)†§ 82.5  14.4
Sulfonylurea use*
Glibenclamide 17 (14.7)
Tolbutamide 31 (26.7)
Gliclazide 7 (6.0)
Glimepiride 17 (14.7)
Data are means  SD or n (%). *At the time of the last A1C
measurement before start of metformin therapy. †At the time of
entrance in the Rotterdam Study. ‡n  114. §n  88.
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metformin therapy.
We identiﬁed nine tagging SNPs in the SLC47A1 gene
and three tagging SNPs (rs2453594, rs2453589, and
rs2165894) in the 10-kbp-downstream region (Table 2).
There were no tagging SNPs in the 10-kbp-upstream
region. For the SNP rs16960201, no genetic variation was
found in the study population. The SNPs rs2441054 and
rs2453568 (r
2  0.84, D0.97) and the SNPs rs2441055
and 1961669 (r
2  0.85, D0.96) were in linkage
disequilibrium. For the other SNPs, no linkage disequilib-
rium was found (r
2  0.8). The genotype distributions of
the eleven tagging SNPs were in Hardy-Weinberg equilib-
rium. In the Caucasian sample of Hapmap, 11 tagging SNPs
cover 25 of 32 (78%) Hapmap SNPs (r
2  0.80) in the
selected gene region (22).
The SNP rs2289669 GA, with a minor allele frequency
of 0.43, was signiﬁcantly associated with a decrease in A1C
level after start of metformin therapy (Table 3). For each
minor A allele, the decrease in A1C level was 0.30% (95% CI
0.51 to 0.10; P  0.005) more (Table 4). For the other
tagging SNPs, no signiﬁcant associations were found. After
Bonferroni correction for multiple testing, this association
remained signiﬁcant (P  0.045).
The rs2289669 genotype distributions did not differ
signiﬁcantly between patients who continued metformin
therapy and those who discontinued at the time of the A1C
measurement after start (
2  1.61, P  0.45). There was
a trend that the decrease in dose of coprescribed sulfonyl-
urea was larger in patients with the AA genotype than in
patients with the GG genotype (Table 5), although this
association was not signiﬁcant (P  0.08).
DISCUSSION
This population-based cohort study in diabetic patients is
the ﬁrst one in which the role of MATE1 in the glucose-
lowering effect of metformin was assessed. We identiﬁed
that the SNP rs2289669 was associated with the A1C-
lowering effect of metformin. The decrease in A1C level
was 0.3% larger per copy of the A allele. These results
suggest that polymorphisms in MATE1 may have a role in
the pharmacokinetics of metformin and, accordingly, with
the glucose-lowering effect. As metformin is recom-
mended as ﬁrst-line treatment for type 2 diabetes, these
results may be valuable for daily clinical practice (18).
The average prescribed daily dose of metformin at the
time of the ﬁrst A1C measurement after start was 741 mg.
The guidelines recommend an initial daily dose of 1,500–
2,000 mg, and this dose may be increased after 10–15 days
to at most 3,000 mg a day. The reason for the low doses of
metformin used in this study may be that the average age
of the study population is 77 years, and physicians are
prudent to prescribe high doses of metformin in this
elderly population because of potential adverse effects.
The average decrease in A1C level (0.6%) is less than what
would be expected when recommended doses are pre-
scribed, and this may explain why the decrease in A1C
level in patients with the GG genotype was near zero and
did not differ signiﬁcantly from zero.
A reduced efﬂux of metformin in the renal brush border
due to an impaired MATE1 transporter will lead to an
increase in metformin plasma levels and possibly to a
larger decrease in glucose levels. Similarly, a reduced
efﬂux from the hepatocyte will lead to higher metformin
levels in the hepatocyte and a stronger inhibition of the
gluconeogenesis, resulting in lower glucose levels. The
TABLE 3
Difference in change of A1C after start of metformin therapy
per genotype
SNP
Adjusted difference
in A1C change (%)* P
P after Bonferroni
correction†
rs894680 0.15 0.19 1.00
rs2018675 0.029 0.80 1.00
rs2440154 0.11 0.35 1.00
rs2440155 0.23 0.10 0.90
rs16960201 — — —
rs2453568 0.09 0.42 1.00
rs2244280 0.23 0.062 0.56
rs2289669 0.30 0.005 0.045
rs1961669 0.16 0.27 1.00
rs2453594 0.26 0.036 0.32
rs2453589 0.12 0.28 1.00
rs2165894 0.28 0.019 0.17
*Additive model (number of variant allele and dose effect), adjusted
for age, sex, A1C level before start, prescribed dose of metformin,
change in prescribed doses of sulfonylurea, time from diagnosis of
diabetes to start of metformin therapy, and estimated glomerular
ﬁltration rate. †We corrected for nine independent tests because one
tagging SNP had no genetic variation and 2 	 2 tagging SNPs were in
linkage disequilibrium.
TABLE 4
Difference in change of A1C after start of metformin therapy for
polymorphism rs2289669
rs2289669 n*
Unadjusted
average
change in
A1C (%)
Adjusted
difference
in A1C
change
(%)† 95% CI P
GG 36 0.28 ref.
GA 58 0.59 0.32 0.65 to 0.01 0.055
AA 21 0.87 0.66 1.19 to 0.14 0.015
Additive 0.30 0.51 to 0.10 0.005
model‡
*In one participant, genotyping for rs2289669 failed.†Adjusted for
age, sex, A1C level before start, prescribed dose of metformin,
change in prescribed doses of sulfonylurea, time from diagnosis of
diabetes to start of metformin therapy, and estimated glomrular
ﬁltration rate. ‡Number of variant alleles.
TABLE 2
Genotyped polymorphisms in the SLC47A1 gene*
SNP AA Aa aa
Minor allele
frequency
Hardy-Weinberg
equilibrium (P)
rs894680 GA 43 58 15 0.38 0.51
rs2018675 CT 43 57 16 0.38 0.67
rs2440154 GA 50 52 14 0.34 0.93
rs2440155 TC 77 35 4 0.19 0.99
rs16960201 — 116 0 0 0 —
rs2453568 CT 58 45 13 0.31 0.35
rs2244280 GA 73 36 7 0.22 0.38
rs2289669 GA 36 58 21 0.43 0.78
rs1961669 AG 79 32 4 0.17 0.73
rs2453594 TC 73 36 7 0.22 0.38
rs2453589 AG 41 56 19 0.38 0.91
rs2165894 AG 68 39 9 0.25 0.32
*Genotyping failed in some participants. Therefore, not all numbers
add up to 116. A, variant allele with the major allele frequency; a,
with minor allele frequency.
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increased glucose-lowering effect, implying that the gene
with the A allele encodes a MATE1 efﬂux transporter less
effective in transporting metformin. This SNP is located in
an intron, and the SNP does not code for an amino acid
change. Most likely, the SNP rs2289669 is in linkage
disequilibrium with a SNP causing the reduced MATE1
functioning, although we cannot exclude that it has a
direct effect, e.g., by affecting gene expression.
One previous study assessed the effect of a SNP in the
SLC47A1 gene on MATE1 expression (24). The authors
identiﬁed a SNP in the promoter region (G-32A) that
downregulates the basal promoter activity. Whether this
SNP affects metformin efﬂux is unknown. Four glutamate
amino acids in MATE1 were found to have an important
role in substrate recognition, although genetic variation in
the nucleotides encoding these amino acids has not been
described (25).
In population-based studies, bias may affect the ob-
tained results. At the time of the ﬁrst A1C measurement
after start, there was a trend toward lower doses of
coprescribed sulfonylurea in patients with the AA geno-
type. This is in line with the results of our study. The
glucose-lowering effect of metformin was stronger in
patients with the AA genotype, and these patients require
less antidiabetes drugs to reach their target levels. In our
analyses, we adjusted for these changes in prescribed
doses of sulfonylurea. The A1C measurements in this
study were done in regular clinical practice. If discontin-
uation of metformin therapy and measurement of A1C
levels were dependent on the genotype, bias might have
occurred. However, no differences in genotype frequency
were found for rs2289669 between patients who continued
metformin until the ﬁrst A1C measurement and patients
who discontinued. Bias may also have occurred if there
were differences in frequency of A1C level measurements.
However, the time from start of metformin therapy until
the ﬁrst A1C measurement did not differ between geno-
types, and neither the prescribing physician nor the pa-
tient was aware of the genetic variation in the SLC47A1
gene. Selection bias is unlikely because we identiﬁed all
incident metformin users in the Rotterdam Study and we
collected information prospectively, without prior knowl-
edge of the study hypothesis. Whether patients give per-
mission to isolate their DNA for scientiﬁc research is most
likely not associated with genetic variation in the
SLC47A1 gene, making selection bias unlikely either.
The Rotterdam Study is a population-based cohort study
on chronic diseases and not primarily designed to assess
the effects of metformin therapy. We identiﬁed 116 pa-
tients who started metformin treatment during follow-up.
This limited sample size may result in both false-negative
results and chance ﬁndings. The SNP rs2289669 was the
SNP with the highest minor allele frequency. Post hoc
power analyses with 
0.00556 (0.05 divided by nine
independent tests) and 0.8 revealed that this sample
size could identify changes in A1C levels for the other
SNPs ranging from 0.44 to 0.56%, dependent on the minor
allele frequency. Therefore, it is possible that we had
false-negative results. We avoided chance ﬁndings by
adjusting for multiple testing with the Bonferroni correc-
tion. Replication of these results in a prospective observa-
tional study or trial is necessary.
To conclude, we found an association between the SNP
rs2289669 in the SLC47A1 gene, encoding the MATE1
transporter, and the glucose-lowering effect of metformin.
In incident metformin users the decrease in A1C level was
0.30% larger per copy of the A allele. These results suggest
that MATE1 may have an important role in the pharmaco-
kinetics and pharmacodynamics of metformin. This is the
ﬁrst epidemiological study assessing the role of MATE1 in
metformin response, and replication of these results is
necessary.
ACKNOWLEDGMENTS
This study was supported by the Netherlands Organisation
for Scientiﬁc Research (175.01.2005.011) and the Nether-
lands Genomics Initiative (050-060-810).
No potential conﬂicts of interest relevant to this article
were reported.
We thank Drs. J.J. Lous for making the STAR-MDC data
available to our study and F. Rivadeneira, P.P. Arp, and M.
Jhamai for help with providing the genotyping data.
REFERENCES
1. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann
Intern Med 137:25–33, 2002
2. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V,
Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI:
Mechanism by which metformin reduces glucose production in type 2
diabetes. Diabetes 49:2063–2069, 2000
3. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I: Polymorphism in human
organic cation transporters and metformin action. Pharmacogenomics
9:415–422, 2008
4. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu
AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM: Effect of genetic
variation in the organic cation transporter 1 (OCT1) on metformin action.
J Clin Invest 117:1422–1431, 2007
5. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y:
Involvement of organic cation transporter 1 in hepatic and intestinal
distribution of metformin. J Pharmacol Exp Ther 302:510–515, 2002
6. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y:
TABLE 5
Cofactors by the rs2289669 polymorphism
GG GA AA
Sex (male) 18 (50) 22 (38) 7 (33)
Age (years) 75.3  7.0 77.9  6.5 75.6  6.1
A1C level before start (%) 8.3  0.9 8.3  1.4 8.4  1.1
Prescribed metformin dose (mg) 853  476 662  262 757  320
Sulfonylurea use (%) 22 (61) 33 (57) 13 (62)
Change in sulfonylurea dose (DDD)* 0.01  0.53 0.17  0.61 0.27  0.52
Time from diabetes diagnosis (years) 5.5  4.4 5.6  4.8 4.7  3.7
Estimated glomerular ﬁltration rate (ml/min) 74  19 68  17 68  14
BMI (kg/m
2) 28.9  3.9 28.1  3.8 27.6  3.2
Data are means  SD or n (%). *P  0.08 for trend. DDD, deﬁned daily dose.
MATE1, METFORMIN, AND DIABETES
748 DIABETES, VOL. 58, MARCH 2009Involvement of organic cation transporter 1 in the lactic acidosis caused by
metformin. Mol Pharmacol 63:844–848, 2003
7. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue
L, Burchard EG, Brett CM, Giacomini KM: Effect of genetic variation in the
organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin
Pharmacol Ther 83:273–280, 2008
8. Kimura N, Okuda M, Inui K: Metformin transport by renal basolateral
organic cation transporter hOCT2. Pharm Res 22:255–259, 2005
9. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K:
Metformin is a superior substrate for renal organic cation transporter
OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379–386,
2005
10. Song I, Shin H, Shim E, Jung I, Kim W, Shon J, Shin J: Genetic variants of
the organic cation transporter 2 inﬂuence the disposition of metformin.
Clin Pharmacol Ther 84:559–562, 2008
11. Wang ZJ, Yin OQ, Tomlinson B, Chow MS: OCT2 polymorphisms and
in-vivo renal functional consequence: studies with metformin and cimeti-
dine. Pharmacogenet Genomics 18:637–645, 2008
12. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y: A
human transporter protein that mediates the ﬁnal excretion step for toxic
organic cations. Proc Natl Acad SciUSA102:17923–17928, 2005
13. Terada T, Inui K: Physiological and pharmacokinetic roles of H/organic
cation antiporters (MATE/SLC47A). Biochem Pharmacol 75:1689–1696,
2008
14. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K: Substrate
speciﬁcity of MATE1 and MATE2-K, human multidrug and toxin extru-
sions/H()-organic cation antiporters. Biochem Pharmacol 74:359–371,
2007
15. Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH,
Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC: The Rotterdam
Study: objectives and design update. Eur J Epidemiol 22:819–829, 2007
16. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA: Determinants
of disease and disability in the elderly: the Rotterdam Elderly Study. Eur
J Epidemiol 7:403–422, 1991
17. WHO Collaborating Centre for Drug Statistics Methodology: Complete ATC
Index 2008. Oslo, World Health Org., 2008
18. American Diabetes Association: Standards of medical care in diabetes,
2008 (Position Statement). Diabetes Care 31 (Suppl. 1):S12–S54, 2008
19. WHO: Deﬁnition, Diagnosis and Classiﬁcation of Diabetes Mellitus and
Its Complications: Part 1. Geneva, World Health Org., 1999
20. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG,
Andrew T, Falchi M, Gwilliam R, Ahmadi KR, Valdes AM, Arp P, Whittaker
P, Verlaan DJ, Jhamai M, Kumanduri V, Moorhouse M, van Meurs JB,
Hofman A, Pols HA, Hart D, Zhai G, Kato BS, Mullin BH, Zhang F, Deloukas
P, Uitterlinden AG, Spector TD: Bone mineral density, osteoporosis, and
osteoporotic fractures: a genome-wide association study. Lancet 371:1505–
1512, 2008
21. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA:
Selecting a maximally informative set of single-nucleotide polymorphisms
for association analyses using linkage disequilibrium. Am J Hum Genet
74:106–120, 2004
22. The International HapMap Consortium: The International HapMap Project.
Nature 426:789–796, 2003
23. Sentrix: HumanHap550 Genotyping Beadchip [article online], 2006. Available
from http://www.illumina.com/downloads/HUMANHAP550_datasheet.pdf. Ac-
cessed 22 July 2008
24. Kajiwara M, Terada T, Asaka J, Ogasawara K, Katsura T, Ogawa O, Fukatsu
A, Doi T, Inui K: Critical roles of Sp1 in gene expression of human and rat
H/organic cation antiporter MATE1. Am J Physiol Renal Physiol 293:
F1564–F1570, 2007
25. Matsumoto T, Kanamoto T, Otsuka M, Omote H, Moriyama Y: Role of
glutamate residues in substrate recognition by human MATE1 polyspeciﬁc
H/organic cation exporter. Am J Physiol Cell Physiol 294:C1074–C1078,
2008
M.L. BECKER AND ASSOCIATES
DIABETES, VOL. 58, MARCH 2009 749